Philips reiterates FY25 outlook following steady Q3 performance

Core Insights - Philips has maintained its fiscal year 2025 guidance, projecting growth between 1% to 3% despite a slight decline in total revenues for Q3 2025 [1][2] - The company reported Q3 comparable sales growth of 3% and an adjusted EBITDA increase of 12.3% to $531 million compared to $516 million in Q3 2024 [2] - The stock closed at €28.02 per share, reflecting a 0.64% decrease from the opening price on November 4 [3] Financial Performance - Total revenues for Q3 2025 were €4.3 billion, a decrease of approximately 1.7% from €4.37 billion in the same period of 2024 [1] - The personal health segment saw the highest comparable sales growth at 10.9%, while diagnosis and treatment grew by 1.3% and Connected Care by 5.1% [4] - The adjusted EBITDA margin is expected to be at the upper end of 11.3% to 11.8% for FY25 [2] Market Position and Strategy - Philips experienced strong order intake and sales growth, particularly in the North American market [5] - The company is focusing on AI-powered innovations and long-term partnerships to enhance its offerings [4] - Investments in the supply chain have been made to mitigate the impact of tariffs related to China on US operations [5]